<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292171</url>
  </required_header>
  <id_info>
    <org_study_id>734275-7</org_study_id>
    <nct_id>NCT04292171</nct_id>
  </id_info>
  <brief_title>Gabapentin for Perioperative Pain Relief in Surgical Abortion</brief_title>
  <official_title>Gabapentin for Perioperative Pain Relief in Surgical Abortion: a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nevada, Las Vegas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nevada, Las Vegas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gabapentin preoperative use for evaluation of benefit to reduce pain during and after
      surgical office-based abortion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind placebo controlled trial of gabapentin in the setting of an ambulatory
      surgical abortion center where patients receive either the routine intravenous sedation,
      local cervical anesthesia plus 600mg of gabapentin one hour prior to surgery vs. the same
      regimen plus placebo one hour prior to surgery. Our primary outcome measure will be
      post-operative validated pain scores using a 11-point visual analog scale (VAS). Secondary
      measures will include nausea and vomiting during, after and 24 hours after the procedure. A
      second and third pain assessment using VAS will be made at 30 minutes and at 24 hours
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind placebo-controlled randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>pharmacy prepared sequentially numbered opaque bottles with identical capsules containing either placebo (vit c) or Gabapentin 600mg, block randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>5 minutes postoperative</time_frame>
    <description>100mm Visual analog scale (VAS) for level of pain, 1-100, 1=no pain, 100= extreme pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score 24</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Pain at 24 hours postoperative on 100mm VAS, 1=no pain, 100=extreme pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Nausea at 24 hours using 100mm VAS, 1=none, 100=extreme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Vomiting at 24 hrs, 100mm VAS, 1=none, 100=extreme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score at 30 minutes postoperative</measure>
    <time_frame>30 minutes postoperative</time_frame>
    <description>100mm Visual analog scale for level of pain, 1-100, 1=no pain, 100= extreme pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Pain Control</condition>
  <arm_group>
    <arm_group_label>Gabapentin Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin 600 mg given 1-2 hours prior to surgical abortion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vit C) given 1-2 hours prior to surgical abortion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Preoperative treatment with Gabapentin</description>
    <arm_group_label>Gabapentin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Preoperative treatment with Placebo</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women seeking surgical abortion between 5 and 23 6/7 weeks of ultrasound age.

          -  English or Spanish speaking

          -  eligible for office-based surgical pregnancy termination

        Exclusion Criteria:

          -  present use of gabapentin or pregabalin,

          -  renal disease

          -  sensitivity or allergy to gabapentin

          -  Missed abortion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vani Dandolu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nevada School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birth Control Care Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nevada, Las Vegas</investigator_affiliation>
    <investigator_full_name>Adam Levy</investigator_full_name>
    <investigator_title>Associate Professor, OB/GYN</investigator_title>
  </responsible_party>
  <keyword>Gabapentin Abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the participant data de-identified that was collected during the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Following publication and terminating 5 years following</ipd_time_frame>
    <ipd_access_criteria>Investigators must submit a Material Transfer Agreement for data transfer between UNLV School of Medicine and investigators institution. Investigators who demonstrate a legitimate proposal on the purpose for the data set, their intended analysis and schedule for anticipated publication will be considered. Investigators should submit their publications within 18 months of receiving the data set.</ipd_access_criteria>
  </patient_data>
  <pending_results>
    <submitted>April 10, 2020</submitted>
    <returned>April 23, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

